Up next

Autoplay

The BAART Clinical Trial: Aripiprazole Vs Risperidone in Autism

0 Views • 08/26/25
Share
Side Effects
Side Effects
Subscribers
0

In this podcast episode, we review the BAART trial on risperidone vs aripiprazole in irritability associated with autism spectrum disorder.

Key Points:
- Psychotherapeutic interventions for autism include applied behavior analysis (ABA) and pivotal response treatment (PRT).
- The FDA has approved the medications risperidone and aripiprazole for irritability associated with autism spectrum disorders.
- Risperidone and aripiprazole did not show a significant difference in efficacy.
- Weight gain and prolactin increase were much higher in risperidone compared to aripiprazole.
- Aripiprazole was more sedating than risperidone (23% and 7% respectively).
- There were no differences in agitation or akathisia between the two agents.

Are you a mental health clinician and want to brush up on psychopharm prescribing? We have what you need! Find the rest of Psychopharmacology Institute podcasts here:

Itunes: https://itunes.apple.com/us/podcast/psychopharmacology-and-psychiatry-updates/id1425185370?mt=2&;app=podcast

Spotify: https://open.spotify.com/show/....7lzv8HKEzNPOAQVpUdrz

Stitcher:
https://www.stitcher.com/s?fid=215561&;amp;refid=stpr

Google Podcasts: https://www.google.com/podcast....s?feed=aHR0cDovL3Bze

RSS:
http://psychopharmacology.libsyn.com/podcast

Website:
https://psychopharmacologyinstitute.com/library?types%5B0%5D=PODCAST&testType=&search=&error=false&page=1

Email us at: [email protected]

Show more
0 Comments sort Sort By

Up next

Autoplay